Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Sheets Smith Wealth Management
Sheets Smith Wealth Management grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 9.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,393 shares of the medical research company’s stock after purchasing an additional 1,121 shares during the period. Sheets Smith Wealth Management’s holdings in Amgen were worth $2,849,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of the business. State Street Corp raised its holdings in shares of Amgen by 19.1% during the third quarter. State Street Corp now owns 31,278,999 shares of the medical research company’s stock worth $7,949,870,000 after purchasing an additional 5,016,641 shares during the period. Morgan Stanley raised its holdings in shares of Amgen by 7.0% during the third quarter. Morgan Stanley now owns 8,565,891 shares of the medical research company’s stock worth $2,177,107,000 after purchasing an additional 561,293 shares during the period. Nuveen Asset Management LLC raised its holdings in shares of Amgen by 2.5% during the third quarter. Nuveen Asset Management LLC now owns 3,997,342 shares of the medical research company’s stock worth $1,015,964,000 after purchasing an additional 95,701 shares during the period. California Public Employees Retirement System raised its holdings in shares of Amgen by 42.8% during the third quarter. California Public Employees Retirement System now owns 1,956,860 shares of the medical research company’s stock worth $497,356,000 after purchasing an additional 586,896 shares during the period. Finally, Candriam Luxembourg S.C.A. raised its holdings in shares of Amgen by 44.9% during the third quarter. Candriam Luxembourg S.C.A. now owns 1,262,359 shares of the medical research company’s stock worth $320,827,000 after purchasing an additional 391,069 shares during the period. 75.23% of the stock is currently owned by institutional investors.
NASDAQ:AMGN traded up $1.15 during trading hours on Wednesday, reaching $237.74. The company’s stock had a trading volume of 1,412,272 shares, compared to its average volume of 2,535,096. The company has a market cap of $138.40 billion, a price-to-earnings ratio of 19.17, a price-to-earnings-growth ratio of 1.85 and a beta of 0.76. Amgen Inc. has a one year low of $177.05 and a one year high of $264.97. The business’s 50-day moving average is $227.94 and its 200-day moving average is $238.44. The company has a debt-to-equity ratio of 3.12, a current ratio of 2.28 and a quick ratio of 1.88.
The company also recently declared a quarterly dividend, which will be paid on Monday, March 8th. Shareholders of record on Monday, February 15th will be issued a dividend of $1.76 per share. This represents a $7.04 dividend on an annualized basis and a yield of 2.96%. This is a boost from Amgen’s previous quarterly dividend of $1.60. The ex-dividend date is Thursday, February 11th. Amgen’s dividend payout ratio is 43.18%.
In other Amgen news, Director R Sanders Williams sold 250 shares of the company’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $242.40, for a total transaction of $60,600.00. Following the completion of the sale, the director now directly owns 4,909 shares in the company, valued at $1,189,941.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.36% of the stock is owned by corporate insiders.
A number of brokerages have weighed in on AMGN. JPMorgan Chase & Co. reissued a “hold” rating on shares of Amgen in a report on Sunday, December 27th. ValuEngine lowered shares of Amgen from a “hold” rating to a “sell” rating in a research report on Thursday, October 8th. Cantor Fitzgerald lowered their price target on shares of Amgen from $279.00 to $278.00 and set an “overweight” rating for the company in a research report on Thursday, October 29th. Bank of America decreased their target price on shares of Amgen from $275.00 to $265.00 and set a “buy” rating for the company in a research report on Thursday, October 29th. Finally, Credit Suisse Group dropped their price target on shares of Amgen from $286.00 to $284.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 27th. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eighteen have issued a buy rating to the stock. Amgen has an average rating of “Hold” and a consensus target price of $254.92.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease.
Read More: Risk Tolerance and Your Investment Decisions
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.